J 2024

Euglykemická ketoacidóza asociovaná se SGLT2 inhibitory a DPP4 inhibitory - rozbor kazuistik

ŠITINA, Michal and Vladimír ŠRÁMEK

Basic information

Original name

Euglykemická ketoacidóza asociovaná se SGLT2 inhibitory a DPP4 inhibitory - rozbor kazuistik

Name (in English)

Euglycemic ketoacidosis associated with SGLT2 inhibitors and DPP4 inhibitors - discussion of case reports

Authors

ŠITINA, Michal (203 Czech Republic, belonging to the institution) and Vladimír ŠRÁMEK (203 Czech Republic)

Edition

Anesteziologie a intenzivní medicína, Praha, Česká lékařská společnost J.E. Purkyně, 2024, 1214-2158

Other information

Language

Czech

Type of outcome

Článek v odborném periodiku

Field of Study

30223 Anaesthesiology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 0.100 in 2022

Organization unit

Faculty of Medicine

UT WoS

001284895400006

Keywords (in Czech)

glifloziny; SGLT2 inhibitory; euglykemická ketoacidóza; hyperchloremická acidóza; diabetes mellitus

Keywords in English

gliflozins; SGLT2 inhibitors; euglycemic ketoacidosis; hyperchloremic acidosis; diabetes mellitus

Tags

Tags

Reviewed
Změněno: 21/8/2024 12:06, Mgr. Tereza Miškechová

Abstract

V originále

Euglycemic ketoacidosis is a rare but potentially fatal complication of treatment with SGLT2 inhibitors (gliflozins). However, similar euglycemic ketoacidosis may rarely occur with other antidiabetic drugs or conditions such as pregnancy or alcohol abuse. We describe 3 cases of our patients with euglycemic ketoacidosis associated with gliflozins and 1 case associated with the DPP4 inhibitor sitagliptin and discuss in detail the acid-base disturbances present and the distinction of euglycemic ketoacidosis from classical ketoacidosis in type 1 diabetes.

In English

Euglycemic ketoacidosis is a rare but potentially fatal complication of treatment with SGLT2 inhibitors (gliflozins). However, similar euglycemic ketoacidosis may rarely occur with other antidiabetic drugs or conditions such as pregnancy or alcohol abuse. We describe 3 cases of our patients with euglycemic ketoacidosis associated with gliflozins and 1 case associated with the DPP4 inhibitor sitagliptin and discuss in detail the acid-base disturbances present and the distinction of euglycemic ketoacidosis from classical ketoacidosis in type 1 diabetes.